JPMorgan downgrades Endava stock rating on execution concerns

JPMorgan downgraded Endava to Underweight from Neutral and cut its price target to $5 from $9 after another quarterly miss and guidance reduction. Fiscal Q3 2026 EPS came in at GBP 0.05 versus GBP 0.21 expected, a 76.2% miss, while revenue was GBP 178.5M versus GBP 183.68M consensus. The stock is down 77% over the past year and trades at $3.34, just above its 52-week low of $3.20, as investors wait for clearer evidence of sustained revenue growth.

Analysis

The immediate loser is not just DAVA holders; it is the entire cohort of mid-cap IT services firms that sell on “growth re-acceleration” but depend on discretionary enterprise spend. When conversion slows and large deals drag, the first-order revenue hit is obvious, but the second-order damage is worse: weaker utilization, lower pricing power, and a longer reset in sales compensation efficiency, which can keep margins depressed even after bookings stabilize. That means any rebound in the group is likely to lag a true macro turn by at least 2-3 quarters, not lead it.

The market is also implicitly telling us that quality of revenue matters more than reported growth. A high mix of time-and-materials can cushion near-term volatility, but it becomes a trap when investors pay for outcome-based upside that never fully scales; the multiple compresses first, then revenue follows. For competitors with cleaner delivery and faster pipeline conversion, this is a share-capture opportunity, especially in engagements where buyers are consolidating vendors and favoring execution certainty over pure headcount scaling.

For JPM, the direct financial impact is limited, but the read-through to sell-side credibility is broader: if management teams continue to miss on the same “temporary” explanations, investors will punish any analyst relying on a quick normalization story. The contrarian case is that the stock may already be discounting a prolonged trough, so a modest improvement in bookings could trigger an outsized squeeze from deeply depressed positioning. But without evidence of sustained sequential growth, rallies should be treated as tradable, not investable, because the path to multiple expansion is still blocked by visibility risk.

Key Decisions for Investors

• Short DAVA on any post-news bounce; use a 1-3 month horizon and cover into sub-$3.25 support. Risk/reward favors 2:1 to 3:1 if revenue guidance is revised lower again, but respect oversold squeezes above $3.80.
• Pair trade: long higher-quality IT services provider with better execution and recurring revenue mix versus short DAVA for 2-4 quarters. The thesis is relative multiple divergence as buyers reward predictability over “turnaround” stories.
• Sell upside call spreads on DAVA rather than outright short if borrow is tight; target the next earnings window. This captures theta while limiting squeeze risk in a name with already-extreme sentiment.
• Avoid catching a falling knife in the broader mid-cap consulting/software services basket until there is one full quarter of sequential bookings improvement. The base case is still margin pressure before a durable revenue inflection.
• For tactical traders, buy DAVA puts into any analyst-driven relief rally, with strikes 10-20% out-of-the-money and expiry beyond the next print. Catalyst-driven downside remains more likely than a sustained rerating.